Agendia, a world leader in molecular cancer diagnostics, announced that its breast cancer product offering, consisting of breast cancer recurrence test MammaPrint(R), and TargetPrint(TM), has been expanded with BluePrint (TM) to report important additional information on tumor subtypes. This new service is based on an 80-gene signature that identifies the basal-like, luminal-like, and HER2 molecular subtypes in breast cancer tumors. "Using BluePrint, we will research potentially different responses of therapies to biologically different subgroups together with our customers... 
More...
More...